ERBB2 and breast carcinoma: In Taiwan, one reason why Her-2-positive subtypes (Luminal B2 and Her-2-enriched) did not receive anti-Her2 target therapy could be that the National Health Insurance only approves this therapy in those with breast cancer with positive lymph node metastasis.